

19



Europäisches Patentamt
European Patent Office
Office européen des brevets

11 Publication number:

0 065 301
A1

12

EUROPEAN PATENT APPLICATION

21 Application number: 82104291.8

51 Int. Cl.³: C 07 C 103/52, A 61 K 37/02

22 Date of filing: 17.05.82

30 Priority: 18.05.81 US 264880
29.03.82 US 362082

71 Applicant: MERCK & CO. INC., 126, East Lincoln Avenue
P.O. Box 2000, Rahway, New Jersey 07065 (US)

43 Date of publication of application: 24.11.82
Bulletin 82/47

72 Inventor: Patchett, Arthur A., 1090 Minisink Way,
Westfield New Jersey 07090 (US)
Inventor: Wu, Mu Tsu, 36 Lance Drive, Clark New
Jersey 07066 (US)


84 Designated Contracting States: AT BE CH DE FR GB IT
LI LU NL SE

74 Representative: Abitz, Walter, Dr.-Ing. et al, Abitz, Morf,
Gritschneider, Freiherr von Wittgenstein
Postfach 86 01 09, D-8000 München 86 (DE)

54 Isoquinoline carboxylic acid derivatives, process for preparing and pharmaceutical composition containing the same.

57 The invention relates to Isoquinoline carboxylic acid derivatives and related compounds of the formula:

which are useful as angiotensin converting enzyme inhibitors and as antihypertensives; process for preparing and pharmaceutical composition containing the same.



wherein:

R and R₄ are hydrogen, loweralkyl, aralkyl;
R₁ is alkyl of from 1 to 10 carbon atoms;
substituted alkyl of from 1 to six carbon atoms;
aralkyl and heteroaralkyl optionally substituted
in the aryl and heteroaryl groups;
R₂ is hydrogen, alkyl of from 1 to six carbon atoms
optionally substituted;
R₃ is hydrogen, halo, or alkoxy; and,
the pharmaceutically acceptable salts thereof;


EP 0 065 301 A1

TITLE OF THE INVENTION

ISOQUINOLINE CARBOXYLIC ACID DERIVATIVES, PROCESS FOR
PREPARING AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

5 BACKGROUND OF INVENTION

10 This invention relates to isoquinoline
carboxylic acid derivatives and related compounds
which are useful as converting enzyme inhibitors and
as antihypertensives. The compounds of this
invention are represented by the following formula:



(I)

wherein

R and R₄ are independently hydrogen, loweralkyl, aralkyl;

5 R₁ is alkyl of from 1 to 10 carbon atoms which include branched, cyclic and unsaturated alkyl groups; substituted alkyl of from 1 to six carbon atoms and the substituent is amino, arylthio, aryloxy, hydroxy, arylamino and acylamino; 10 aralkyl and heteroaralkyl optionally substituted in the aryl and heteroaryl groups by halo, loweralkyl, hydroxy, alkoxy, amino, and aminoalkyl groups and optionally substituted in the C₁-C₆ alkyl groups by 15 amino, acylamino or hydroxy groups; R₂ is hydrogen, alkyl of from 1 to six carbon atoms optionally substituted by amino, alkylamino, arylamino, acylamino, 20 heteroaryl, or aryl groups; R₃ is hydrogen, halo, or alkoxy; and, the pharmaceutically acceptable salts thereof.

The loweralkyl groups, except where noted otherwise, represented by any of the variables 25 include straight and branched chain hydrocarbon radicals of from one to six carbon atoms such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, hexyl or vinyl, allyl, butenyl, and the like. The aralkyl groups 30 represented by any of the above variables have from one to four carbon atoms in the alkyl portion thereof and include, for example, benzyl, phenethyl, and the

like. Halo means chloro, bromo, iodo or fluoro.
Aryl where it appears in any of the radicals, except
where noted, represents phenyl, or naphthyl and
heteroaryl includes, for example, indolyl, thienyl,
5 quinoliny, isoquinoliny, imidazolyl, furyl, pyridyl
and benzothienyl. Heteroaralkyl indicates that these
same residues are attached to 1-4 carbon atoms and
include, for example, indolyethyl, 1-iso-
quinolinylmethyl, and the like. Acylamino refers to
10 loweralkanoylamino and aroylamino groups.

Preferred are those compounds of Formula I
wherein:

R and R₄ are independently hydrogen, loweralkyl,
and aralkyl;
15 R₁ is alkyl of from 1 to 6 carbon atoms optionally
substituted by amino, hydroxyl, acylamino,
aryloxy, arylthio, aralkyl and heteroaralkyl
wherein the aryl and heteroaryl groups may
optionally be substituted by halo,
20 loweralkyl, hydroxy, alkoxy, amino and
aminoalkyl groups;

R₂ is alkyl of from 1 to 6 carbon atoms optionally
substituted by amino, heteroaryl, or
aminoloweralkylthio groups; and,

25 R₃ is hydrogen.

Still more preferred are those compounds of
Formula I wherein R is hydrogen, loweralkyl; and
R₁, R₂ and R₃ are as defined in the preferred
compounds above.

30 Most preferred are compounds of Formula I
wherein:

R and R₄ are independently hydrogen or loweralkyl;

R_1 is aralkyl or heteroaralkyl optionally substituted by halo or aminoalkyl groups;
 R_2 is alkyl of from 1 to 6 carbon atoms optionally substituted by amino or aminoloweralkylthio groups; and,

5

R_3 is hydrogen.

The preferred, more preferred and most preferred compounds also include the pharmaceutically acceptable salts thereof.

10

The compounds of this invention can be synthesized by the methods described hereinbelow. Unless otherwise indicated, starting materials required for these syntheses are known in the literature or can be made by known methods using known starting materials.

15


Interfering functionality in the starting materials such as, for example, hydroxy, carboxy or amino groups, can be masked by protecting groups which can then be subsequently removed to afford desired end products. Appropriate protecting groups are well known to those skilled in the art of peptide chemistry, some of which are illustrated in the processes described herein.

20

In the following description of the invention processes, R, R_1 , R_2 , R_3 and R_4 are as defined above, unless otherwise indicated.

25

30

REACTION SCHEME

With reference to the foregoing Reaction Scheme, dipeptide analog II is synthesized by coupling an α -blocked amino acid (for example, Z=carbobenzyloxy or t-butoxycarbonyl) with an isoquinoline ester using appropriate reagents such as, for example, dicyclohexyl carbodiimide or diphenylphosphoryl azide. The Z protecting group is removed using standard methods and R can then be taken off of the isoquinoline carboxylate by saponification. The α -keto acids or esters containing the R_1 substituent are then reductively added to compound II. This can be conveniently accomplished using sodium cyanoborohydride in a mixed aqueous solvent at approximately neutral pH or by hydrogenation in an inert solvent in the presence of Pd/C or Raney nickel. Removal of protecting groups, if present, affords the desired products of Formula I.

The carbon atoms to which R_1 and R_2 are attached and the asymmetric carbon in the isoquinoline ring of Formula I compounds are all preferably of the S absolute configuration. Other diastereomers in which an R configuration is present also exhibit activity and are, therefore, also included within the scope of this invention. Preferred Formula I diastereomers are isolated either by chromatography or fractional crystallization.

The α -ketocarboxylate derivatives used in the reductive alkylation can include such compounds as, for example, ethyl 2-oxo-4-phenylbutyrate, ethyl 4-p-chlorophenyl-2-oxobutyrate, ethyl 4-(4-imidazolyl)-2-oxobutyrate, ethyl 2-oxo-4-(2-thienyl)-butyrate, ethyl 2-oxo-4-(2-naphthyl)-

butyrate, ethyl 4-p-hydroxy-phenyl-2-oxobutyrate,
ethyl phenoxypyruvate, ethyl 2-oxo-5-phenyl-
pentanoate, ethyl 4-p-methoxyphenyl-2-oxobutyrate,
ethyl 5-methyl-2-oxohexanoate, benzyl 2-oxo-6-
5 phthalimido-hexanoate, and the like, and their
respective free acids.

The compounds of this invention form salts
with various inorganic and organic acids and bases
which are also within the scope of the invention.
10 Such salts include ammonium salts, alkali metal salts
like sodium and potassium salts, alkaline earth metal
salts like the calcium and magnesium salts, salts
with organic bases e.g., dicyclohexylamine salts,
N-methyl-D-glucamine, salts with amino acids like
15 arginine, lysine, and the like. Also, salts with
organic and inorganic acids may be prepared, e.g.,
HCl, HBr, H_2SO_4 , H_3PO_4 , methanesulfonic,
toluenesulfonic, maleic, fumaric, camphorsulfonic.
The non-toxic physiologically acceptable salts are
20 preferred, although other salts are also useful,
e.g., in isolating or purifying the product.

The salts may be formed by conventional
means as by reacting the free acid or free base forms
of the product with one or more equivalents of the
25 appropriate base or acid in a solvent or medium in
which the salt is insoluble, or in a solvent such as
water which is then removed in vacuo or by
freeze-drying or by exchanging the cations of an
existing salt for another cation on a suitable ion
30 exchange resin.

The compounds of this invention inhibit angiotensin converting enzyme and thus block conversion of the decapeptide angiotensin I to angiotensin II. Angiotensin II is a potent pressor substance. Thus blood-pressure lowering can result from inhibition of its biosynthesis especially in animals and humans whose hypertension is angiotensin II related. Furthermore, converting enzyme degrades the vasodepressor substance, bradykinin. Therefore, inhibitors of angiotensin converting enzyme may lower blood-pressure also by potentiation of bradykinin. Although the relative importance of these and other possible mechanisms remains to be established, inhibitors of angiotensin converting enzyme are effective antihypertensive agents in a variety of animal models and are useful clinically, for example, in many human patients with renovascular, malignant and essential hypertension. See, for example, D. W. Cushman et al., Biochemistry 16, 5484 (1977).

The evaluation of converting enzyme inhibitors is guided by in vitro enzyme inhibition assays. For example, a useful method is that of Y. Piquilloud, A. Reinhartz and M. Roth, Biochem. Biophys. Acta, 206, 136 (1970) in which the hydrolysis of carbobenzyloxyphenylalanylhistidinyl-leucine is measured. In vivo evaluations may be made, for example, in normotensive rats challenged with angiotensin I by the technique of J. R. Weeks and J. A. Jones, Proc. Soc. Exp. Biol. Med., 104, 646 (1960) or in a high renin rat model such as that of S. Koletsky et al., Proc. Soc. Exp. Biol. Med. 125, 96 (1967).

Thus, the compounds of this invention are useful as antihypertensives in treating hypertensive mammals, including humans, and they can be utilized to achieve the reduction of blood pressure by
5 formulating in compositions such as tablets, capsules or elixirs for oral administration or in sterile solutions or suspensions for parenteral administration. The compounds of this invention can be administered to patients in need of such treatment
10 in a dosage range of 1.0 to 200 mg per patient generally given several times, thus giving a total daily dose of from 1.0 to 800 mg per day. The dose will vary depending on severity of disease, weight of patient and other factors which a person skilled in
15 the art will recognize.

Also, the compounds of this invention may be given in combination with diuretics or other antihypertensives. Typically, these are combinations whose individual per day dosages range from one-fifth
20 of the minimally recommended clinical dosages to the maximum recommended levels for the entities when they are given singly. To illustrate these combinations, one of the antihypertensives of this invention, effective clinically in the range 15-200 milligrams
25 per day, can be effectively combined at levels ranging from 3-200 milligrams per day with the following antihypertensives and diuretics in dose ranges per day as indicated:
30 hydrochlorothiazide (15-200 mg), timolol (5-60 mg), methyldopa (65-2000 mg), the pivalyloxyethyl ester of methyldopa (30-1000 mg), indacrinone and variable

ratios of its enantiomers (25-125 mg), and (+)-4-{3-
[[2-(1-hydroxycyclohexyl)ethyl]-4-oxo-2-thiazolidinyl]
propyl}-benzoic acid (10-100 mg).

In addition, the triple drug combinations of
5 hydrochlorothiazide (10-100 mg) plus amiloride (5-20
mg) plus converting enzyme inhibitor of this
invention (3-200 mg) or hydrochlorothiazide (10-100
mg) plus timolol (5-60 mg) plus the converting enzyme
inhibitor of this invention (3-200 mg) are effective
10 combinations to control blood pressure in
hypertensive patients.

The above dose ranges will be adjusted on a
unit basis as necessary to permit divided daily
dosage. Also, the dose will vary depending on the
15 severity of the disease, weight of patient and other
factors which a person skilled in the art will
recognize.

Typically the combinations shown above are
formulated into pharmaceutical compositions as
20 discussed below.

About 1.0 to 100 mg of a compound or mixture
of compounds of Formula I or a physiologically
acceptable salt is compounded with a physiologically
acceptable vehicle, carrier, excipient, binder,
25 preservative, stabilizer, flavor, etc., in a unit
dosage form as called for by accepted pharmaceutical
practice. The amount of active substance in these
compositions or preparations is such that a suitable
dosage in the range indicated is obtained.

30

Illustrative of the adjuvants which may be incorporated in tablets, capsules and the like are the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as microcrystalline cellulose; a disintegrating agent such as corn starch, pregelatinized starch, alginic acid, and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, lactose or saccharin; a flavoring agent such as peppermint, oil of wintergreen or cherry. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as fatty oil. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

Sterile compositions for injection can be formulated according to conventional pharmaceutical practice by dissolving or suspending the active substance in a vehicle such as water for injection, a naturally occurring vegetable oil like sesame oil, coconut oil, peanut oil, cottonseed oil, etc. or a synthetic fatty vehicle like ethyl oleate or the like. Buffers, preservatives, antioxidants and the like can be incorporated as required.

The following examples are illustrative of the invention and constitute especially preferred

embodiments. The preferred diastereomers of these examples are isolated by conventional column chromatography or fractional crystallization. Unless otherwise indicated, all temperatures are in degrees Celsius.

EXAMPLE 1

2-[N^α-(1-Carboxy-3-phenylpropyl)-L-lysyl]-L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid

α-t-BOC-ξ-CBZ-L-lysine and ethyl 1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylate are condensed in the presence of N,N'-dicyclohexylcarbodiimide.


15 The ethyl ester is hydrolyzed by stirring in ethanolic sodium hydroxide (1.3 eq.) at room temperature for 22 hours. The resulting sodium salt is stirred in 4N HCl in EtoAc at room temperature for 1 hour to remove the t-BOC group. The hydrochloride

20 salt (1.48 mmol) and 2-oxo-4-phenylbutyric acid (1.32 g, 7.40 mmol) are dissolved in 50% ethanol and neutralized to pH 7 with dilute sodium hydroxide. A solution of sodium cyanoborohydride (279 mg, 4.44 mmol, in 5 ml of ethanol) is added by syringe pump at

25 the rate of 1.5 ml/hr. After several days stirring at room temperature, the product is absorbed on strong acid ion exchange resin (Dowex 50 (H⁺), 50-100 mesh). The column is rinsed to pH 6 with water, then eluted with 2% pyridine in water.

30 Product rich cuts are evaporated to a white solid (595 mg., 67%). The solid is dissolved in methanol and purified by LH-20 gel filtration chromatography. This procedure reveals the presence of a substantial

amount (~50%) of the corresponding diketopiperazine compound as a contaminant. The pure product obtained above is stirred in 30% HBr in glacial acetic acid for 15 minutes at room temperature to remove the CBZ protecting group. The free amine is obtained after treatment of the HBr salt with Dowex 50 (H^+). The final product, 2-[N $^{\alpha}$ -(1-carboxy-3-phenylpropyl)-L-lysyl]-L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, is freeze dried from water containing several drops of methanol as a white fluffy solid (135 mg. 0.29 mmol, 18% overall yield). The nmr spectrum confirmed this structure. The mass spectrum shows a molecular ion at m/e 683 for the trisilylated species; m/e 668 for loss of methyl from the trisilyl; m/e 566 for loss of -CO₂TMS from the trisilyl; and m/e 407 for the common fragment,



EXAMPLE 2

25 2-[N-(1-Carbethoxy-3-phenylpropyl)-L-alanyl]-L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid

CBZ-L-alanine and ethyl 1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylate are condensed in the presence of N,N'-dicyclohexylcarbodiimide. Hydrolysis of the ethyl ester is accomplished by stirring in ethanolic sodium hydroxide (1.5 eq) at room temperature overnight. The resulting sodium

salt is stirred in 30% HBr in glacial acetic acid for 1 hour at room temperature to remove the CBZ protecting group. The free amine is obtained from the HBr salt by treatment with Dowex 50 (H^+).

5 2-(L-Alanyl-L-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (234 mg., 0.942 mmol) and ethyl 2-oxo-4-phenylbutyrate (971 mg., 4.71 mmol) are dissolved in 80 ml of absolute ethanol. To this solution is added 1.6 g of 4A powdered molecular

10 sieves. A solution of sodium cyanoborohydride (177 mg., 2.83 mmol, in 5 ml of EtOH) is added to this suspension by syringe pump at the rate of 1 ml/hr. After stirring at room temperature for several days, the reaction mixture is filtered to remove molecular

15 sieves and stripped to a yellow viscous oil. The oil is stirred with Dowex 50 (H^+) in a mixture of water and ethanol for 1 hour. This mixture is then added to a Dowex 50 (H^+) (50-100 mesh) column packed with 50% EtOH. The column is washed to pH 5 6 with 50%

20 EtOH, then water. The product is then eluted with 2% pyridine in water. Product rich cuts are stripped to a gummy solid (256 mg., 62%). The crude product is purified by LH-20 gel filtration chromatography. The purified product is essentially water insoluble and

25 is freeze dried from dioxane as a thick gum. The nmr spectrum is consistent with structure.

EXAMPLE 3

2-[N-(1-Carboxy-3-phenylpropyl)-L-alanyl]-L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid

5 Ethyl ester (140 mg., 0.32 mM) in Example 2, was dissolved in 0.5 ml of methanol, 1.0 ml of 1 M NaOH was added and the solution was stirred at room temperature overnight. The solution was acidified with dilute hydrochloric acid and concentrated in
10 vacuo. The residue was applied to a 240 X 0.9 cm LH-20 column and eluted with 3 l fractions of methanol. Concentration of fractions 47-58 gave 69 mg (53%) of 2-[N-(1-carboxy-3-phenylpropyl)-L-alanyl]-L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic
15 acid as a white solid after freeze drying; tlc (4-ethyl acetate: 1-acetic acid with Anal. Tech SGF mini plate): Rf = 0.92 and 0.88; 200 MH nmr (deuteromethanol): consistent; mass spectrum (trimethylsilylated): m/e 626.

20


EXAMPLE 4

As illustrated in the above example, keto acids and esters listed in Table I below can be reductively condensed using sodium cyanoborohydride
25 with the dipeptides L-alanyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and ϵ -Cbz-L-lysyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid to yield additional products of Formula I as listed in Table II below.


30

TABLE I
Keto Acids and Esters


R₁CO-CO₂R




5




10



15




20




25




30




(h)




(i)




(j)




(k)




(l)




(m)



(n)



(o)








TABLE II
ADDITIONAL PRODUCTS OF FORMULA I



(R₃ = R₄ = H)


R	R ₁	R ₂
(1) Et	(CH ₃) ₂ CH-CH ₂	CH ₃ -

(2) H




NH₂(CH₂)₄-

(3) H













CH₃-

(4) C₆H₅-CH₂-




NH₂(CH₂)₄-

- 5 (5) CH_3  CH_3^-
- (6) H $\text{CH}_3\text{S}-\text{CH}_2\text{CH}_2^-$ $\text{NH}_2(\text{CH}_2)_4^-$
- 10 (7) CH_3 $\text{H}_2\text{N}(\text{CH}_2)_4^-$ CH_3^-
- 15 (8) H  CH_3^-
- 20 (9) H  $\text{NH}_2(\text{CH}_2)_4^-$
- 25 (10) H  CH_3
- 30 (11) H  $\text{NH}_2(\text{CH}_2)_4^-$

5	(12) Et		CH_3
	(13) H		$\text{NH}_2(\text{CH}_2)_4^-$
10	(14) H	$(\text{CH}_3)_2\text{CH}-\text{CH}_2\text{CH}_2-$	CH_3
	(15) Et		CH_3
15			
	(16) H		CH_3
20			
	(17) H		$\text{NH}_2(\text{CH}_2)_4^-$
25			
30			

WHAT IS CLAIMED IS:

1. A compound of the formula:



wherein:


R and R₄ are independently hydrogen, loweralkyl, aralkyl;

- 15 R₁ is alkyl of from 1 to 10 carbon atoms which include branched, cyclic and unsaturated alkyl groups; substituted alkyl of from 1 to six carbon atoms and the substituent is amino, arylthio, aryloxy, hydroxy, arylamino and acylamino;
- 20 aralkyl and heteroaralkyl optionally substituted in the aryl and heteroaryl groups by halo, loweralkyl, hydroxy, alkoxy, amino, and aminoalkyl groups and optionally substituted in the C₁-C₆ alkyl groups by amino, acylamino or hydroxy groups;
- R₂ is hydrogen, alkyl of from 1 to six carbon atoms optionally substituted by amino, alkylamino, arylamino, acylamino, heteroaryl, or aryl groups;

R_3 is hydrogen, halo, or alkoxy; and,
the pharmaceutically acceptable salts thereof.

2. A compound of Claim 1 which is a member
of the group:
- 2-[N^{α} -(1(S)-carboxy-3-phenylpropyl)-L-lysyl]-L-
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
- 2-[N-(1(S)-carboxy-3-phenylpropyl)-L-alanyl]-L-1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid; and,
- 2-[N-(1(S)-carboethoxy-3-phenylpropyl)-L-alanyl]-
L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.

3. A pharmaceutical composition useful in
the treatment of hypertension which comprises a
pharmaceutically acceptable carrier and an
antihypertensively effective amount of a compound of
the formula:




wherein:

- R and R_4 are independently hydrogen, loweralkyl
aralkyl;
- R_1 is alkyl of from 1 to 10 carbon atoms which
include branched, cyclic and unsaturated
alkyl groups;

substituted alkyl of from 1 to six carbon
atoms and the substituent is amino, arylthio,
aryloxy, hydroxy, arylamino and acylamino;
aralkyl and heteroaralkyl optionally
5 substituted in the aryl and heteroaryl groups
by halo, loweralkyl, hydroxy, alkoxy, amino,
and aminoalkyl groups and optionally
substituted in the C₁-C₆ alkyl groups by
amino, acylamino or hydroxy groups;
10 R₂ is hydrogen, alkyl of from 1 to six carbon atoms
optionally substituted by amino, alkylamino,
arylamino, acylamino, heteroaryl, or aryl
groups;
R₃ is hydrogen, halo or alkoxy; and,
15 the pharmaceutically acceptable salts thereof.

4. The composition of Claim 3 which includes
an antihypertensive and/or diuretic compound selected
from the group consisting of hydrochlorothiazide,
20 methyldopa, timolol, the pivalyloxyethyl ester of
methyldopa, indacrinone and variable ratios of its
enantiomers, (+)-4-{3-[2-(1-hydroxycyclohexyl)-
ethyl]-4-oxo-2-thiazolidinyl}propyl} benzoic acid, as
well as admixtures and combinations thereof.
25

5. A process for preparing a compound of the formula:




10 wherein R, R₁, R₂, R₃ and R₄ are as defined in Claim 1, which comprises:

reacting an α-keto acid or ester having the formula:



wherein R and R₁ are as defined in Claim 1 and R₁ can include suitable protection of reactive groups, with a dipeptide or protected dipeptide analog of the formula:



wherein R₂, R₃ and R₄ are as defined in Claim 1 and R₂ can include suitable protecting groups, in the presence of a reducing agent, followed by removal of protecting groups, if present, to afford the desired product; and, if further desired, isolating

30

1705
0065301

- 25 -

16607IA

the biologically more active isomer by chromatography or fractional crystallization and, if still further desired, forming a salt thereof by standard means.

5

10

15


20

25

30

CLAIMS FOR AUSTRIA

1. A process for preparing a compound of the formula:




wherein:

R and R₄ are independently hydrogen, loweralkyl, aralkyl;


15 R₁ is alkyl of from 1 to 10 carbon atoms which include branched, cyclic and unsaturated alkyl groups; substituted alkyl of from 1 to six carbon atoms and the substituent is amino, arylthio, aryloxy, hydroxy, arylamino and acylamino;

20 R₂ is hydrogen, alkyl of from 1 to six carbon atoms optionally substituted by amino, alkylamino, arylamino, acylamino, heteroaryl, or aryl groups;

- 1 R_3 is hydrogen, halo, or alkoxy; and,
the pharmaceutically acceptable salts thereof,
which comprises
reacting an α -keto acid or ester having the
5 formula:



- wherein R and R_1 are defined as above and R_1
can include suitable protection of reactive groups,
10 with a dipeptide or protected dipeptide analog of the
formula:



- 20 wherein R_2 , R_3 and R_4 are defined as above
and R_2 can include suitable protecting groups, in
the presence of a reducing agent, followed by removal
of protecting groups, if present, to afford the
desired product; and, if further desired, isolating
25 the biologically more active isomer by chromatography
or fractional crystallization and, if still further
desired, forming a salt thereof by standard means.

- 30 2. A process according to claim 1 for
preparing a compound which is a member of the group:

1

2-[N^α-(1(S)-carboxy-3-phenylpropyl)-L-lysyl]-L-
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;

5

2-[N-(1(S)-carboxy-3-phenylpropyl)-L-alanyl]-L-1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid; and,

2-[N-(1(S)-carboethoxy-3-phenylpropyl)-L-alanyl]-
L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.

10

15

20

25

30

35



European Patent
Office

EUROPEAN SEARCH REPORT

0065301
Application number

EP 82 10 4291

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 3)
P,X	EP - A - 0 049 605 (WARNER-LAMBERT) * whole patent * ---	1-3,5	C 07 C 103/52 A 61 K 37/02
P,X	EP - A - 0 049 658 (SCIENCE UNION) * whole patent * ---	1-5	
P,X	EP - A - 0 046 953 (HOECHST) * whole patent * -----	1-5	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 3)
			C 07 C 103/00 C 07 D 217/00 A 61 K 37/00
The present search report has been drawn up for all claims			
Place of search The Hague		Date of completion of the search 16.06.1982	Examiner GRAMAGLIA
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	